Eiko LifeSciences Limited (BOM:540204)
India · Delayed Price · Currency is INR 46.65
+0.21 (0.45%)
At close: Aug 21, 2026
Eiko LifeSciences Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 587.44 | 527.07 | 376.64 | 279.29 | 183.21 | 254.12 |
Other Revenue | 1.46 | - | -0 | - | - | - |
| 588.9 | 527.07 | 376.64 | 279.29 | 183.21 | 254.12 | |
Revenue Growth | 54.55% | 39.94% | 34.85% | 52.44% | -27.90% | 111.93% |
Cost of Revenue | 465.22 | 412.95 | 328.05 | 254.16 | 161.14 | 226.16 |
Gross Profit | 123.67 | 114.11 | 48.59 | 25.14 | 22.07 | 27.96 |
Selling, General & Admin | 7.4 | 6.66 | 7.23 | 2.73 | 3.68 | 2.82 |
Other Operating Expenses | 36.18 | 33.07 | 13.76 | 6.28 | 8.85 | 11.98 |
Operating Expenses | 53.74 | 49.9 | 28.36 | 15.63 | 18.85 | 20.42 |
Operating Income | 69.94 | 64.22 | 20.23 | 9.5 | 3.22 | 7.53 |
Interest Expense | -4.12 | -3.3 | -1.53 | -1.42 | -1.5 | -3.69 |
Interest & Investment Income | - | - | 6.93 | 1.82 | 7.27 | 6.42 |
Earnings From Equity Investments | 0.77 | 0.53 | 1.43 | - | - | - |
Currency Exchange Gain (Loss) | - | - | 0.03 | -0.06 | 0.96 | 0.11 |
Other Non Operating Income (Expenses) | 9.73 | 9.73 | -0.06 | -0 | 0 | -0.95 |
EBT Excluding Unusual Items | 76.32 | 71.18 | 27.04 | 9.84 | 9.95 | 9.42 |
Gain (Loss) on Sale of Investments | - | - | 0.2 | - | 0.32 | - |
Gain (Loss) on Sale of Assets | - | - | 0 | - | - | - |
Other Unusual Items | - | - | 3.41 | - | - | - |
Pretax Income | 76.32 | 71.18 | 30.65 | 9.84 | 10.26 | 9.42 |
Income Tax Expense | 19.16 | 17.93 | 7.46 | 2.33 | 2.58 | 2.36 |
Earnings From Continuing Operations | 57.16 | 53.25 | 23.19 | 7.52 | 7.69 | 7.06 |
Minority Interest in Earnings | -8.26 | -8.28 | -2.13 | - | - | - |
Net Income | 48.9 | 44.96 | 21.06 | 7.52 | 7.69 | 7.06 |
Net Income to Common | 48.9 | 44.96 | 21.06 | 7.52 | 7.69 | 7.06 |
Net Income Growth | 79.17% | 113.53% | 180.20% | -2.25% | 8.94% | 14.88% |
Shares Outstanding (Basic) | 14 | 14 | 13 | 10 | 10 | 8 |
Shares Outstanding (Diluted) | 15 | 14 | 13 | 10 | 10 | 8 |
Shares Change | 12.58% | 8.12% | 26.37% | 5.41% | 25.30% | 104.48% |
EPS (Basic) | 3.51 | 3.26 | 1.62 | 0.73 | 0.79 | 0.90 |
EPS (Diluted) | 3.27 | 3.19 | 1.62 | 0.73 | 0.79 | 0.90 |
EPS Growth | 59.15% | 97.49% | 121.73% | -7.26% | -12.72% | -44.03% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 22.84 | -73.67 | -74.26 | 39.99 | -78.82 |
Free Cash Flow Per Share | - | 1.62 | -5.65 | -7.20 | 4.09 | -10.09 |
Gross Margin | 21.00% | 21.65% | 12.90% | 9.00% | 12.05% | 11.00% |
Operating Margin | 11.88% | 12.18% | 5.37% | 3.40% | 1.76% | 2.96% |
Profit Margin | 8.30% | 8.53% | 5.59% | 2.69% | 4.20% | 2.78% |
Free Cash Flow Margin | - | 4.33% | -19.56% | -26.59% | 21.83% | -31.02% |
EBITDA | 80.79 | 74.38 | 27.6 | 16.13 | 9.55 | 13.16 |
EBITDA Margin | 13.72% | 14.11% | 7.33% | 5.78% | 5.21% | 5.18% |
D&A For EBITDA | 10.86 | 10.16 | 7.37 | 6.63 | 6.33 | 5.62 |
EBIT | 69.94 | 64.22 | 20.23 | 9.5 | 3.22 | 7.53 |
EBIT Margin | 11.88% | 12.18% | 5.37% | 3.40% | 1.76% | 2.96% |
Effective Tax Rate | 25.11% | 25.19% | 24.35% | 23.64% | 25.09% | 25.09% |
Revenue as Reported | 598.62 | 536.79 | 383.8 | 281.05 | 191.76 | 260.85 |
Advertising Expenses | - | - | 0.06 | 0.1 | 0.06 | 0.05 |